Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Tuesday and Wednesday Index of Poster Presenters cont’d 17P16 The Use of Global Hemostatic Measures to Monitor Response to Bypassing Agent Therapy During Orthopaedic Surgery in a Patient with Severe Hemophilia and a Factor VIII Inhibitor Biss T1 , Knaggs K2 , Varty P1 , Talks K1 1Newcastle Regional Haemophilia Centre, The Newcastle upon Tyne Hospitals NHS Trust, U.K., 2Department of Haematology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Trust, U.K. 17P17 Pro-Pact: Retrospective Prophylaxis Patient Case Collection of rFVIIa Treatment in Hemophilia Patients with Inhibitors Blanchette V, on behalf of the PROPACT Steering Committee Hospital for Sick Children, Toronto, ON, Canada 17P18 Risk Factors of Inhibitor in 321 PUPS with Severe Hemophilia A: Results of the FranceCoag Network Calvez T1 , d’Oiron R2 , Donadel-Claeyssens S3 , Héritier V4 , Vinciguerra C5 , Goudemand J6 1 2 Inserm & UPMC UMR-S 943, Paris, France, Haemophilia Centre of Kremlin Bicêtre, France, 3Haemophilia Centre of Toulouse, France, 4French Institute for Public Health 5 Surveillance, Saint-Maurice, France, Haematology Department, Lyon-Herriot, France, 6Haemophilia Centre of Lille, France 17P19 Single Dose rFVIIa for Severe Hemophilia A (HA) with Inhibitors: Report of the Experience in Argentina Perez Bianco R1, 2 , Candela M2 , Neme D1 1Fundacion Nacional de la Hemofilia - Buenos Aires, Argentina., 2Instituto de Investigaciones Hematologicas “Mariano R. Castex” - Academia Nacional de Medicina - Buenos Aires, Argentina 17P20 Incidence of Inhibitors at the Algiers Hemophilia Center (Algeria) Chennoukh K, Bensadok M, Berkouk Y, Louanchi L, Kaci Z, Belhani M Department of Hematology and Blood Banking, University Hospital of Beni Messous, Algiers, Algeria 17P21 Prophylactic Treatment with FEIBA and Subsequent Immune Tolerance Induction Therapy to Improve Inhibitor Eradication on Hemophilia A Patients With Inhibitor Chien S, Chen Y Tri-Service General Hospital, Taipei City, Taiwan 68 17P22 Evaluation of Room Temperature Stable Recombinant Activated Factor VII During Continuous Infusion: Product and Microbiological Stability Over 24 Hours Cooper D 1 , Christensen A 2 , Jensen J 2 , Nøhr A 2 1 Novo Nordisk Inc., Princeton, NJ, U.S.A., 2 Novo Nordisk A/S, Gentofte, Denmark 17P23 Immune Tolerance Induction (ITI) With a FVIII Concentrate with High VWF Content in Inhibitor Patients With Previous Unsuccessful ITI and/or Negative Predictors of ITI Response Coppola A1 , Arbasi M2 , Biasoli C3 , Messina M4 , Tagliaferri A5 , Scaraggi F6 1Regional Reference Centre For Coagulation Disorders, Federico II University Hospital, Milan, Italy, 2Centre for Bleeding Disorders, Transfusion Medicine, Hospital of Piacenza, 3Transfusion and Haemophilia Centre, Bufalini Hospital, Cesena, 4Paediatric Regional Reference Centre for Bleeding and Thrombotic Disorders, Regina Margherita Children Hospital, Turin, 5Regional Reference Centre for Haemophilia, University Hospital, Parma, 6Haemostasis and Thrombosis Centre, Dep. of Internal Medicine, University of Bari, Bari, Italy 17P24 Predictors of Success in Immune Tolerance Induction (ITI) in Hemophilia A Patients with High-Responding Inhibitors: The Italian ITI Registry Coppola A, Margaglione M, Santagostino E, Rocino A, Castaman G, Iorio A Regional Reference Centre for Coagulation Disorders, Federico II University Hospital, Milan, Italy 17P25 Pharmacokinetics of Factor VIII Concentrates in Subjects with Hemophilia A Who Are Bethesda Negative for Factor VIII Inhibitors and ELISA Positive for Antibodies Reacting with Different Factor VIII Preparations Rivard G1 , Dedeken L1 , Vincent A1 , Lillicrap D2 , Meilleur C1 , Fan L1 1 2 CHU Sainte-Justine, Montreal, Canada, Queen’s University, Kingston, Canada 17P26 The Use of Bypassing Agents in Factor VIII and IX Inhibitors: A European Survey Dolan G, Holme PA Nottingham University Hospital, Nottingham, U.K., Rikshospitalet, Oslo, Norway, on behalf of the European Haemophilia Therapy Standardisation Board (EHTSB)
Index of Poster Presenters cont’d 17P27 F8 Haplotype and Recombinant Product Use in the Hemophilia Inhibitor Genetics Study (HIGS) Schwarz J1 , Donfield S1 , Winkler C2 , Binns-Roemer E2 , Berntorp E3 , Astermark J3 and the HIGS Study Group 1 2 Rho, Inc., Chapel Hill, NC, U.S.A., National Cancer Institute at Frederick, Frederick, MD, U.S.A., 3Malmö University Hospital, Malmö, Sweden 17P28 Functional-Molecular Magnetic Resonance Imaging for Early Characterization of Hemophilic Arthropathy in a Rabbit Model Doria A1 , Amirabadi A1 , Miller E2 , Cheng H1 , Zhong A1 , Sussman M3 1The Hospital For Sick Children, Toronto, ON, Canada 2Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, 3Toronto General Hospital, Toronto, ON, Canada 17P29 New INSIGHT in Inhibitor Development in Mild/Moderate Hemophilia A: Inhibitors Arise After More Exposure Days than in Severe Disease Eckhardt C, Peters M, Fijnvandraat K Paediatric Haematology, Emma Children’s Hospital, Amsterdam, the Netherlands 17P30 Surgery as a Risk Factor for Inhibitor Development in Hemophilia A: A Systematic Review Eckhardt C1, 2 , Van der Bom J3 , Van der Naald M2 , Peters M1 , Kamphuisen P2 , Fijnvandraat K1 1Paediatric Haematology, Emma Children’s Hospital, Amsterdam, the Netherlands, 2Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands, 3Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands 17P31 A Sensitive and Specific Chromogenic Assay for the Detection of “Functional FVIII Inhibitors” Ghosh K, Pinto P, Kulkarni B, Shetty S Department of Haemostasis and Thrombosis, National Institute of Immunohaematology (ICMR), KEM Hospital, Mumbai, India 17P32 Surgery and Transfusions Are Associated With Higher Inhibitor Incidence in 104 PUPS With Severe Hemophilia A Goudemand J1 , Bridey F2 , Rothschild C3 , Gruel Y4 , Vinciguerra C5 , Grouin J6 , Négrier C7 , Calvez T8 , Tellier Z2 1 2 3 Haemophilia Centres of Lille, LFB, Les Ulis, Paris-Necker, 4 5 6 Tours, Haematology Department, Lyon-Herriot, University of Rouen, 7Lyon-Herriot, 8Inserm & UPMC UMR-S 943, Paris, France 17P33 Determinants of High Titer Inhibitor Development: The Canal Study Gouw S 1,2 , Mancuso E 3 , Santagostino E 3 , van den Berg M 2, 4 , van der Bom J 5 1 Department of Paediatrics, Wilhelmina Children’s Hospital, UMCU, the Netherlands, 2 Department of Laboratory Medicine, University Medical Center Utrecht, Utrecht, the Netherlands, 3 Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation and University of Milan, Milan, Italy, 4 Meander Medical Center, Amersfoort, the Netherlands, 5 Department of Clinical Epidemiology, Leiden University Medical Center, the Netherlands 17P34 Sequential Combined Bypassing Therapy is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Hemophilia and Inhibitors Gringeri A1 , Fisher K2 , Karafoulidou A3 , Klamroth R4 , López- Fernández M5 , Mancuso E1 1Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione Ospedale Maggiore Policlinico and University of Milan, Milan, Italy, 2Van Creveldkliniek, Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands, 32nd Blood Transfusion Center and Hemophilia Center, Laikon General Hospital, Athens, Greece, 4Hämophilie-Zentrum, Am Vivantes-Klinikum in Friedrichshain Zentrum für Gefäßmedizin Berlin, Germany, 5Servicio de Hematología y Hemoterapia, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain 17P35 A Comparison of Prescribed and Actual Recombinant Factor VIIa (rFVIIa) Dosing in Pediatric Versus Adult Patients with Congenital Hemophilia With Inhibitors (CHwI): Analysis of the Dosing Observational Study in Hemophilia (DOSE) Gruppo R1 , Kessler C2 , Neufeld E3 , Shapiro A4 , Cooper D5 , Carr, Jr. M5 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, U.S.A., 2Georgetown University Medical Center, Washington, DC, U.S.A. 3Childrens Hospital of Boston, MA, U.S.A., 4Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, U.S.A. 5Novo Nordisk Inc., Princetown, NJ, U.S.A. 17P36 International Prospective Randomised Immune Tolerance (ITI) Study: Interim Analysis of Therapeutic Efficacy and Safety Hay C1 , Goldberg I2 , Foulkes M1 , DiMichele D2 1 2 University Dept of Haematology, Manchester, U.K., Weill Medical College of Cornell University, U.S.A. 69 Posters, Tuesday and Wednesday
Page 1 and 2:
Hemophilia Saturday, July 10 - Wedn
Page 3 and 4: Pre-Congress Sessions cont’d 10:3
Page 5 and 6: Pre-Congress Sessions cont’d 15:0
Page 7 and 8: Congress Sessions cont’d S1.6 - M
Page 9 and 10: Congress Sessions cont’d S2.5 - M
Page 11 and 12: Congress Sessions cont’d n Long T
Page 13 and 14: Congress Sessions cont’d M2.4 - M
Page 15 and 16: Congress Sessions cont’d Tuesday,
Page 17 and 18: Congress Sessions cont’d 14:15 -
Page 19 and 20: Congress Sessions cont’d T3.4 - M
Page 21 and 22: Congress Sessions cont’d n Inhibi
Page 23 and 24: Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 53: Index of Poster Presenters cont’d
show all

Final Program in it's entirety - MyGirlsBlood

Create successful ePaper yourself

Delete template?

Save as template?